Samarth Kulkarni Sells 18,360 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) CEO Samarth Kulkarni sold 18,360 shares of the firm's stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the transaction, the chief executive officer now directly owns 171,613 shares in the company, valued at $9,473,037.60. This trade represents a 9.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Samarth Kulkarni also recently made the following trade(s):

• On Monday, December 2nd, Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $55.10, for a total value of $826,500.00.

CRISPR Therapeutics Stock Down 5.0 %

NASDAQ CRSP traded down $2.52 during trading on Friday, hitting $47.91. The company's stock had a trading volume of 2,671,174 shares, compared to its average volume of 2,550,435. The firm has a 50 day moving average price of $42.25 and a 200 day moving average price of $46.04. The firm has a market cap of $4.11 billion, a P/E ratio of -10.96 and a beta of 1.67. CRISPR Therapeutics AG has a 52 week low of $36.52 and a 52 week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, equities analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CRSP. ARK Investment Management LLC increased its position in CRISPR Therapeutics by 19.7% in the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company's stock worth $353,180,000 after buying an additional 1,474,439 shares during the period. T. Rowe Price Investment Management Inc. grew its holdings in shares of CRISPR Therapeutics by 39.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company's stock worth $150,029,000 after purchasing an additional 1,074,238 shares in the last quarter. Capital International Investors grew its holdings in shares of CRISPR Therapeutics by 10.3% during the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company's stock worth $344,145,000 after purchasing an additional 816,789 shares in the last quarter. Baker BROS. Advisors LP grew its holdings in shares of CRISPR Therapeutics by 743.1% during the 3rd quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company's stock worth $39,608,000 after purchasing an additional 743,075 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company's stock worth $140,611,000 after purchasing an additional 599,304 shares in the last quarter. 69.20% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on CRSP shares. Chardan Capital decreased their target price on CRISPR Therapeutics from $94.00 to $84.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. Evercore ISI upgraded CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and increased their price target for the company from $60.00 to $99.00 in a research report on Friday, February 14th. StockNews.com upgraded CRISPR Therapeutics to a "sell" rating in a research report on Thursday, February 13th. Stifel Nicolaus decreased their price target on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating for the company in a research report on Thursday, February 13th. Finally, Bank of America decreased their price objective on CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $74.40.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.